TY - JOUR
T1 - Progress and challenges towards targeted delivery of cancer therapeutics
AU - Rosenblum, Daniel
AU - Joshi, Nitin
AU - Tao, Wei
AU - Karp, Jeffrey M.
AU - Peer, Dan
N1 - Funding Information:
This work was supported in part by grants from the Leona M. and Harry B. Helmsley Nanotechnology Research Fund, the Len and Susan Mark Ovarian Cancer Fund, the Israel Science Foundation (1178/16), the Dotan Center for Hemato-Oncology at Tel Aviv University, the Lewis Trust for Blood Cancer, and by the ERC grant LeukoTheranostics (# 647410) awarded to D.P. This work was also supported in part by the Prostate Cancer Foundation and NIH R01 grant HL095722 to J.M.K.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/4/12
Y1 - 2018/4/12
N2 - Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.
AB - Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.
KW - Antineoplastic Agents/chemistry
KW - Drug Approval/legislation & jurisprudence
KW - Drug Carriers
KW - Drug Compounding/methods
KW - Humans
KW - Molecular Targeted Therapy/methods
KW - Nanomedicine/methods
KW - Nanoparticles/administration & dosage
KW - Neoplasms/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85045523734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045523734&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-03705-y
DO - 10.1038/s41467-018-03705-y
M3 - Review article
C2 - 29650952
AN - SCOPUS:85045523734
SN - 2041-1723
VL - 9
SP - 1410
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1410
ER -